Adhera Therapeutics Signs Letter of Intent with Melior Pharmaceuticals II to Acquire a New Class of Drug for Parkinson’s Disease
07 juin 2021 08h45 HE
|
Adhera Therapeutics, Inc.
Adhera to acquire and develop MLR-1019 (armesocarb), the API in mesocarb – a drug previously sold in Europe for 37 years – for Parkinson’s DiseaseMLR-1019, a Phase 2-ready product, could have...
IMAC Holdings, Inc. Announces Completion of First Cohort of its Phase 1 Clinical Study of Umbilical Cord-Derived Mesenchymal Stem Cells for the Treatment of Bradykinesia Due to Parkinson’s Disease
01 mars 2021 09h25 HE
|
IMAC Holdings, Inc.
BRENTWOOD, Tenn, March 01, 2021 (GLOBE NEWSWIRE) -- IMAC Holdings, Inc. (Nasdaq: IMAC) (“IMAC” or “the Company”), today announces it has completed the first cohort of its Phase 1 clinical trial for...
Parkinson’s Disease Market Value Anticipated To Reach US$ 4,764.3 Mn By 2027: Acumen Research And Consulting
03 févr. 2021 13h44 HE
|
Acumen Research and Consulting
Acumen Research and Consulting, a global provider of market research studies, in a recently published report titled “Parkinson’s disease Market– Global Industry Analysis, Market Size, Opportunities...
Parkinson’s Disease Therapeutic Market revenue to cross USD 8 Bn by 2027: Global Market Insights, Inc.
26 janv. 2021 06h00 HE
|
Global Market Insights, Inc
Selbyville, Delaware, Jan. 26, 2021 (GLOBE NEWSWIRE) -- According to latest report “Parkinson’s Disease Therapeutic Market by Drug Class (Levodopa/Carbidopa, Dopamine Agonists, Adenosine A2A...
Mike Fox introduces a travel book narrating his wife’s treatment for Parkinson’s disease in Italy
02 sept. 2020 02h08 HE
|
AuthorHouseUK
TORQUAY, England, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Author Mike Fox offers a travel book/autobiography advocating awareness for Parkinson’s disease. This year, he announces the release of his...
Trevi Therapeutics Announces Positive Outcome of the Sample Size Re-Estimation Analysis in PRISM Trial for Severe Pruritus in Patients With Prurigo Nodularis
13 juil. 2020 07h30 HE
|
Trevi Therapeutics
Independent Data Monitoring Committee Recommends Continuation of PRISM Trial with Expansion to 360 Subjects per the Adaptive Design Enrollment Expected to be Complete by Third Quarter 2021 ...
Adamas Reports Second Quarter 2018 Financial Results
02 août 2018 16h01 HE
|
Adamas Pharmaceuticals, Inc.
- GOCOVRI™ (amantadine) extended release capsules product sales reached $7.6 million for the second quarter - EMERYVILLE, Calif., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc....
Adamas Pharmaceuticals Launches “Dyskinesia Is A Jerk™,” a Campaign to Raise Awareness and Highlight the Impact of Parkinson’s Disease Dyskinesia
01 août 2018 09h00 HE
|
Adamas Pharmaceuticals, Inc.
- Despite significant impact on daily life and the ability to treat primary symptoms of Parkinson’s disease dyskinesia (uncontrolled jerking or twisting movements), symptoms are often not recognized...
Adamas Presents New Data Analysis Demonstrating that GOCOVRI™ Reduces Transitions between Dyskinesia and OFF Episodes Throughout the Day
22 juin 2018 09h12 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., June 22, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced the presentation of new data analysis of GOCOVRI™ (amantadine) extended release...
Adamas Announces Publication of Pharmacokinetic Data for GOCOVRI™ in Clinical Pharmacokinetics
24 mai 2018 09h05 HE
|
Adamas Pharmaceuticals, Inc.
EMERYVILLE, Calif., May 24, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that pharmacokinetic (PK) data regarding GOCOVRI™ (amantadine) extended release...